Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

February 28, 2006

Study Completion Date

June 30, 2010

Conditions
Desmoid Tumor
Interventions
DRUG

imatinib mesylate

Trial Locations (23)

13385

CHU de la Timone, Marseille

14076

Centre Regional Francois Baclesse, Caen

25030

Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besançon

31052

Institut Claudius Regaud, Toulouse

33076

Institut Bergonie, Bordeaux

34298

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier

35042

Centre Eugene Marquis, Rennes

37044

Centre Hospitalier Universitaire Bretonneau de Tours, Tours

44805

CRLCC Nantes - Atlantique, Nantes-Saint Herblain

49036

Centre Paul Papin, Angers

51056

Institut Jean Godinot, Reims

54511

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

59020

Centre Oscar Lambret, Lille

67065

Centre Paul Strauss, Strasbourg

67091

Hopitaux Universitaire de Strasbourg, Strasbourg

69373

Centre Leon Berard, Lyon

69437

Hopital Edouard Herriot - Lyon, Lyon

75248

Institut Curie Hopital, Paris

75970

Hopital Tenon, Paris

76038

Centre Henri Becquerel, Rouen

92151

Hopital Foch, Suresnes

92211

Centre Rene Huguenin, Saint-Cloud

F-94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

UNICANCER

OTHER

NCT00287846 - Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis | Biotech Hunter | Biotech Hunter